estrone
Approved
Jun 12, 1941
Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. It’s used as hameopatic in management of premenopausal and postmenopausal symptoms. In 1929, Butenandt isolated estrone from the urine of pregnant women. Estrone is known to be a carcinogen for human females as well as a cause of breast tenderness or pain, nausea, headache, hypertension, and leg cramps in the context of non-endogenous exposure. In men, estrone has been known to cause anorexia, nausea, vomiting, and erectile dysfunction. Estrone is relevant to health and disease states because of its conversion to estrone sulfate, a long-lived derivative. Estrone sulfate acts as a reservoir that can be converted as needed to the more active estradiol. — NCATS
Clinical trial activity
3 trials · 3 clinical orgs · 5 marketing orgs
Earliest trial started Jun 1, 2005 (NCT00239148)
Timeline
1920s
- Jul 1, 1929
Evidence of US Marketing
1940s
- Jun 12, 1941
Parke-Davis — Earliest FDA Approval
- Jun 12, 1941
Parke-Davis — NDA Secondary Org
- Jun 12, 1941
Parke-Davis — NDA Organization
1970s
- Feb 21, 1979
Teva — Marketing Organization
- Feb 21, 1979
Dr. Reddy's Laboratories — Marketing Organization
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Estrogen receptor alphaAGONIST
ESR1 agonist
Approval history
- approvedJun 12, 1941
- approvedJul 1, 1929
Chemistry & pharmacology
SMILES
Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2- Mol. weight
- 454.91 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL282724 ↗
- WikipediaEstrone ↗
- NCATS2DI9HA706A ↗
- ChEMBLCHEMBL2105740 ↗
- ChEMBLCHEMBL1405 ↗
Also known as
- 3-hydroxy-1,3,5(10)-estratrien-17-one
- 3-hydroxy-1,3,5(10)-estratrien-17-one
- e1
- e1
- estrogenic substance
- estrogenic substance
- estron
- estrona
- estrona
- estrone
- estrone
- estrone
- estrone
- estrone
- estrone
- estrone
- estrone
- estrone
- estrone
- estronum
- estronum
- estrugenone
- follicular hormone
- follicular hormone
- folliculin
- folliculin
- oestrin
- oestrone
- oestrone
- oestrone
- oestrone
- theelin
- theelin
- theelin
- thelin
- thelin
- thelin
- thelin
- thelin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00744211 | N/A | Jul 31, 2008 | Department of Veteran Affairs, Medical University of South Carolina |
| NCT00239187 | Phase 1 | Sep 1, 2005 | Transition Therapeutics |
| NCT00239148 | Phase 1 | Jun 1, 2005 | Transition Therapeutics |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Transition Therapeutics | For profit | 2 | 2 | 1 | 2005 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2008 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2008 |
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Home Products | For profit | MKTG | — |
| Dr. Reddy's Laboratories | For profit | MKTG | Feb 21, 1979 |
| Parke-Davis | For profit | NDA2 | Jun 12, 1941 |
| Parke-Davis | For profit | NDA | Jun 12, 1941 |
| Teva | For profit | MKTG | Feb 21, 1979 |
| Watson Pharmaceuticals | For profit | MKTG | — |